CARLSBAD, CALIFORNIA–(Marketwired – Oct. 21, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today that it has entered into a worldwide distribution and co-marketing agreement with Sentio, LLC to distribute the Sentio MMG® nerve mapping system.
Sentio has pioneered a game changing method for mapping nerve location, resulting in improved technology for surgeons to use as compared to traditional techniques. Sentio MMG® is a surgical access tool used to locate and map motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2.
“This co-marketing strategy strengthens our position at the forefront of minimally invasive spine surgery technologies,” said Trent J. Northcutt, President and CEO of Aurora Spine. “We are excited about our relationship with Sentio MMG® in conjunction with our VOX™ MIS lateral interbody system featuring TiNANO™. The Sentio system was specifically designed to facilitate safe MMG monitoring during any MIS spine surgery. Aurora and Sentio share a vision to improve spine patient outcomes, drive continued surgeon interest, and bolster relevance as key innovators in spine.”
“Aurora’s MIS, tech-company culture fits extremely well with Sentio. We share a common ethos that will help drive both organizations to success as we co-market our technologies,” said Sean Parker, Sentio’s Vice President of Market Development.
Sentio MMG smart-sensors employ a proprietary technology, using non-invasive accelerometer-based sensors to measure MMG (mechanomyography) activity, or the mechanical “twitch” associated with muscle contraction. The result is an intuitive, surgeon-directed tool for establishing safe access in a variety of surgical applications.
Sentio is currently cleared for use in the United States by the FDA to assist in locating and mapping motor nerves through the use of mechanomyographic signals and electrical stimulus of nerves. Sentio MMG has a CE mark for use in European Union and other markets.
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.